John Wiley & Sons, Inc.: 11/10/13 Background and Purpose Intravenous tissue plasminogen activator is the most effective treatment for acute ischemic stroke, and its use may therefore serve as an indicator of the available level of acute stroke care. The greatest burden of stroke is in low- and middle-income countries, but the extent to which intravenous […]
STROKEAHA: November 7, 2013 Background and Purpose—The favorable cardiovascular effects attributed to adiponectin may lower risk of stroke. We investigated this in a prospective study and meta-analysis. Methods—A case–cohort study nested within the Potsdam cohort of the European Prospective Investigation into Cancer was performed, with 170 incident cases of ischemic stroke and a randomly selected subcohort […]
J NeuroIntervent Surg: 11/6/13 Every year almost 800 000 people in the USA suffer a new or recurrent stroke, and stroke is the third leading cause of death with over 140 000 deaths in the USA in 1995.1 Additionally, stroke is a leading cause of long-term disability with an estimated cost of $68.9 billion in 2009. The relationship between […]
JAMA: November 6, 2013 Importance Rates of testosterone therapy are increasing and the effects of testosterone therapy on cardiovascular outcomes and mortality are unknown. A recent randomized clinical trial of testosterone therapy in men with a high prevalence of cardiovascular diseases was stopped prematurely due to adverse cardiovascular events raising concerns about testosterone therapy safety. Objectives To assess the […]
STROKEAHA: November 5, 2013 Research Priorities in the Assessment of Neurothrombectomy Devices Background and Purpose—The goal of the Stroke Treatment Academic Industry Roundtable (STAIR) meetings is to advance the development of stroke therapies. At STAIR VIII, consensus recommendations were developed for clinical trial strategies to demonstrate the benefit of endovascular reperfusion therapies for acute ischemic stroke. […]
STROKEAHA: October 30, 2013 Background and Purpose—The Centers for Medicare and Medicaid Services proposes to use 30-day hospital readmissions after ischemic stroke as part of the Hospital Inpatient Quality Reporting Program for payment determination beginning in 2016. The proportion of poststroke readmissions that is potentially preventable is unknown. Methods—Thirty-day readmissions for all Medicare fee-for-service beneficiaries aged […]
STROKEAHA: October 30, 2013 Background and Purpose—Women are more likely to have a worse outcome after an acute stroke than men. Some studies have suggested that women also benefit less from intravenous thrombolysis after an acute ischemic stroke, but others found no sex differences in safety and efficacy. We aimed to evaluate differences in 3-month outcome […]
The American Heart Associatio: October 28, 2013 The Value of Disease-Based Registries in Improving Quality and Outcomes The American Heart Association/American Stroke Association (AHA/ASA) is a trusted source of scientific information in cardiovascular medicine. The AHA/ASA has a longstanding commitment to support state-of-the-art scientific research in cardiovascular disease and stroke. The AHA/ASA has also developed a leadership role in translating cardiovascular science […]
American Heart Association: October 28, 2013 Since the initial scientific statement on Secondary revention of Coronary Heart Disease (CHD) in the Elderly was published in 2002,1 several trends have continued hat make an update highly appropriate. First, the graying of the US population and those of other industrialized ountries has progressed unabated because more adults are surviving into their senior […]
JAMA: 9/2/13 Identification of the role that plasma lipid components play in the pathogenesis of ischemic heart disease is one of the major successes of biomedical research in the 20th century. It has led to successful public health and individual-level interventions for lowering cholesterol levels as part of the strategy for prevention of ischemic heart disease. […]
